Deep Genomics vs Kepler Vision

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Deep Genomics employs 100-500 people, while Kepler Vision has 1-50 employees.

Deep Genomics has raised $180M in disclosed funding across 0 known rounds. Kepler Vision's funding history is not publicly available.

Deep Genomics holds the higher Awaira Score at 68/100, compared to Kepler Vision's 30/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 38-point gap that reflects meaningful differences in scale or traction.

Deep Genomics was founded by Brendan Frey in 2015. Kepler Vision was founded by Harro Stokman in 2017. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. Kepler Vision: Kepler Vision Technologies develops AI fall detection and activity recognition software for elderly care environments, using computer vision models that process video from ceiling-mounted cameras in care facilities to detect falls, assess resident activity patterns, and alert care staff to incidents requiring immediate response. The Amsterdam company platform is designed to operate without wearables or pressure sensors, relying entirely on camera-based analysis to provide unobtrusive monitoring.\n\nThe company is early stage with initial funding from Dutch innovation programmes and care sector partners. Kepler Vision has piloted its Night Nurse product in Dutch residential care facilities, where staff shortages create demand for AI monitoring tools that can maintain safety oversight overnight when staffing ratios are lowest. The platform is designed to comply with European privacy regulations governing personal data processing in care environments, using on-device processing to avoid transmitting identifiable video to cloud services.\n\nKepler Vision operates in the AI elder care market alongside CarePredict, SafelyYou, and camera-based monitoring startups targeting the intersection of computer vision and residential care. The European elder care AI market faces distinct regulatory challenges compared to the US, with GDPR-compliant video monitoring in care facilities requiring explicit consent frameworks and data minimisation approaches. The Netherlands position as a leader in healthcare technology innovation and its advanced residential care infrastructure make it a relevant test market for technology that addresses the growing caregiver shortage across European social care systems.

Deep Genomics was founded first in 2015, giving it 2 years of additional market experience. Kepler Vision was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Deep Genomics has approximately 100-500 employees, while Kepler Vision has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Deep Genomics and Kepler Vision are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.